""
UC Davis Medicine Logo
The institution's principal publication for alumni, friends and physicians.
""
Horizontal boundary
""
""
"" "" ""
  N E W S  
"" "" ""
"" Eye drops may delay, prevent glaucoma ""
""

 

""
"" Japan, U.S. lung cancer patients react differently ""
""

 

""
  Novel drug in phase 2 trial  
""

 

""
  Study may refine youth violence prevention efforts  
""

 

""
  Deaths at pediatric ICUs studied  
""

 

""
  Timing may be critical with oral anti-cancer agents  
     
  CDC director delivers commencement address  
     
  Hormone therapy may still be an option  
     
  Man's sight restored after 38 years  
     
  UC Davis economic impact tops $2.7 billion annually  
     
  Smoking tied to cancer death burden in African-American men  
     
  MRI study sheds new light on attention processes  
     
  A perfect match  
     
  Fortified OJ may lower 'bad' cholesterol  
     
  Memory, emotion brain areas larger in children with autism  
     
  ER docs see increase in uninsured patients  
     
  Construction under way  
Vertical Seperator Line
  NEWS
"" ""
""
"" ""
"" ""
 
""

Novel drug in phase 2 trial

A three-drug combination, including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results reported recently at the annual meeting of the American Society of Clinical Oncologists.

The triple-therapy regimen will now be tested nationally in a phase II trial as first-line therapy for advanced non-small cell lung cancer. Angela Davies, assistant professor of hematology and oncology at UC Davis Cancer Center and principal investigator of the phase I trial, will also lead the phase II trial.

The regimen consists of bortezomib, gemcitabine and carboplatin. Gemcitabine and carboplatin represent an accepted first-line treatment combination for advanced non-small cell lung cancer. Bortezomib is a proteasome inhibitor that blocks the signals cancer cells rely on to degrade cellular proteins. The result is a buildup of proteins that hastens cell death

""
"" ""
 
"" ""
"" ""
Vertical Seperator Line
"" "" ""
     
"" "" Vertical Seperator Line "" "" "" ""
"" "" Vertical Seperator Line
""
""

UC DAVIS SCHOOL OF MEDICINE
PUBLIC AFFAIRS
4900 Broadway, Suite #1200
Sacramento, CA 95820

ucdavismedicine@ucdmc.ucdavis.edu

© 2004 UC Regents. All rights reserved.

"" "" ""